Adaptive Biotechnologies (ADPT) News Today

Millennium Management LLC grew its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 1,008.3% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 9,262,341 shares of the company's stock after acquiring an additional 8,426,

Federated Hermes Inc. reduced its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 95.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,272 shares of the company's stock a

Rubric Capital Management LP lifted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 33.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,000,000 shares of the company's stock after purc

Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to

Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 5.2%

Adaptive Biotechnologies (NASDAQ:ADPT) Trading 8.4% Higher

Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 3.2%

Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 9,660,000 shares, a decrease of 11.8% from the July 31st total of 10,950,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is currently 6.6 days.

Legato Capital Management LLC lifted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 63.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 209,702 shares of the company's stock after acquiring an

Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating

Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 8.6%

Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 11.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,899,631 shares of the company's sto

Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 9.5%

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 4.8%

Price T Rowe Associates Inc. MD reduced its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 47.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 155,229 shares of the company's stock after selling 13

Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) - Analysts at William Blair increased their Q3 2024 earnings per share estimates for Adaptive Biotechnologies in a research note issued on Wednesday, August 7th. William Blair analyst A. Brackmann now forecasts that the company will post ea

Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 10.6%

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) released its earnings results on Thursday. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02. Adaptive Biotechnologies had a negative return on equity of 57.43% and a negative net margin of 126.49%. The firm had revenue of $43.19 million during the quarter, compared to analysts' expectations of $38.63 million. During the same period in the prior year, the company earned ($0.33) earnings per share. The company's quarterly revenue was down 11.7% on a year-over-year basis.

Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four ha

JPMorgan Chase & Co. increased their price objective on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an "overweight" rating in a report on Friday.

Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Down to $4.45

Acadian Asset Management LLC acquired a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 162,137 shares of the company's stock, valued at approx

Adaptive Biotechnologies (NASDAQ:ADPT) Trading 9.2% Higher

Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 6.7%